News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Novartis Successfully Concludes Acquisition of Chinook Therapeutics
Monday, August 14, 2023Novartis has successfully concluded its acquisition of Chinook Therapeutics Inc a biopharmaceutical company headquartered in Seattle WA The acquisition valued at a potential USD billion is aligned with Novartis strategic focus on advancing precision...
Immatics Launches Phase 1/2 Clinical Trial to Evaluate IMA402, a Bispecific PRAME TCR, in Patients With Late-stage Solid Tumors
Friday, August 11, 2023Immatics NV NASDAQ IMTX has announced the commencement of a Phase clinical trial for its novel Bispecific T cell Engaging Receptor TCER IMA representing a significant step in the development of T cellredirecting cancer immunotherapies
Sosei Heptares and Cancer Research UK Have Initiated a Phase I/IIa Trial, Marking the Administration of the First Dose of the Cancer Immunotherapy Drug HTL0039732
Friday, August 11, 2023Sosei Group Corporation TSE and Cancer Research UK have jointly initiated a Phase IIIa clinical trial to assess a novel cancer immunotherapy drug known as HTL
Alzecure Announces Positive Outcomes From Phase I Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
Thursday, August 10, 2023AlzeCure Pharma AB publ FN STO ALZCUR is a pharmaceutical company dedicated to the development of small molecule candidate drugs targeting disorders of the central nervous system
Pliant Therapeutics Introduces the BEACON-IPF Phase 2b Clinical Trial to Evaluate Bexotegrast's Potential in Treating Idiopathic Pulmonary Fibrosis
Thursday, August 10, 2023Pliant Therapeutics Inc a biotechnology company listed on Nasdaq under the symbol PLRX has announced the initiation of a Phase b clinical trial named BEACONIPF
Phase III Trials of Novartis' Remibrutinib Successfully Achieve Primary Endpoints and Indicate Swift Symptom Management in Chronic Spontaneous Urticaria
Wednesday, August 09, 2023Novartis has revealed positive outcomes from two Phase III trials REMIX and REMIX which assessed the effectiveness of remibrutinib a Brutons tyrosine kinase BTK inhibitor in managing chronic spontaneous urticaria CSU patients who exhibit insufficient...
Biophytis Receives Positive Evaluation for Phase 3 SARA-31 Trial Addressing Sarcopenia in Europe
Tuesday, August 08, 2023Biophytis SA a biotechnology company listed on Nasdaq CM BPTS and Euronext Growth Paris ALBPS has received favorable feedback from Belgian authorities to initiate the innovative SARA initiative
Bavarian Nordic Releases Positive Phase 3 Topline Findings for Chikungunya Virus Vaccine in Adults and Adolescents
Monday, August 07, 2023Bavarian Nordic AS OMX BAVA has recently unveiled positive topline results from a Phase clinical trial NCT for their chikungunya virus vaccine candidate CHIKV VLP PXVX
Evox Therapeutics Teams Up to Progress Next-Generation Exosome-Mediated AAV Gene Therapy for Heart Disease Treatment
Saturday, August 05, 2023Evox Therapeutics Ltd a prominent biotech company specializing in exosome therapeutics has recently announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai Icahn Mount Sinai in New York NY
Askbio Commences Phase 1/phase 2 Clinical Study of AB-1003 Gene Therapy for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Friday, August 04, 2023Asklepios BioPharmaceutical Inc AskBio a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG
